Journal articleAm J Transplant · August 2015
Featured Publication
Vascularized composite allotransplantation (VCA) has emerged as a viable limb replacement strategy for selected patients with upper limb amputation. However, allograft rejection has been seen in essentially all reported VCA recipients indicating a requirem ...
Full textLink to itemCite
Journal articleAm J Transplant · August 2015
Featured Publication
Vascularized composite allografts (VCAs) are technically feasible. Similar to other organ transplants, VCAs are hampered by the toxicity and incomplete efficacy associated with conventional immunosuppression. Complications attributable to calcineurin inhib ...
Full textLink to itemCite
OtherTransplantation · June 15, 2012
Featured Publication
To date, there are more than 80 reports of vascularized composite allografts (VCAs; a.k.a. composite tissue allotransplantation). However, the classification of this type of transplantation for oversight purposes has not been clarified. From a biological a ...
Full textLink to itemCite
Journal articleAm J Transplant · January 2011
Featured Publication
Like all other areas of transplantation, vascularized composite allografts (VCA) has the capacity to transform the lives of patients, for the better or for the worse. It is this duality that mandates VCA be performed in centers prepared for the intricacies ...
Full textLink to itemCite
Journal articleAm J Transplant · July 2008
Featured Publication
Composite tissue allotransplantation (CTA) is a recently introduced option for limb replacement and reconstruction of tissue defects. As with other allografts, CTA can undergo immune-mediated rejection; therefore standardized criteria are required for char ...
Full textLink to itemCite
Book section · January 1, 2008
Featured Publication
Patients suffering from severe tissue loss secondary to burns, traumatic injuries, or tumor resections have limited options for reconstruction when autologous tissue for reconstruction is scarce. Composite tissue allotransplantation (CTA) has recently been ...
Full textCite
Journal articleTransplantation · February 15, 2006
Featured Publication
BACKGROUND: Composite tissue allotransplantation (CTA) is a recently introduced option for limb replacement and reconstruction of other nonreconstructible tissue defects. As with recipients of other allotransplants, CTA recipients can experience rejection ...
Full textLink to itemCite
Journal articleTransplantation · November 27, 2005
Featured Publication
BACKGROUND: Composite tissue allotransplantation (CTA) has been recently introduced as a potential treatment for tissue loss secondary to burns, injuries, or resections. However, the optimal strategies to prevent CTA rejection remain undefined. Presently, ...
Full textLink to itemCite
Journal articleTransplantation · October 27, 2005
Featured Publication
BACKGROUND: Perioperative lymphocyte depletion induces allograft tolerance in some animal models, but in humans has only been shown to reduce immunosuppressive requirements. Without maintenance immunosuppression, depleted human renal allograft recipients e ...
Full textLink to itemCite
Journal articleJ Am Coll Surg · April 2005
Featured Publication
BACKGROUND: Chronic allograft nephropathy (CAN) remains the leading cause of late renal allograft loss that is minimally responsive to therapy once graft dysfunction is clinically evident. A screening test capable of identifying individuals at high risk fo ...
Full textLink to itemCite
Journal articleAm J Transplant · March 2005
Featured Publication
Renal allograft acute cellular rejection (ACR) is a T-cell mediated disease that is diagnosed histologically. However, many normally functioning allografts have T-cell infiltrates and histological ACR, and many nonimmune processes cause allograft dysfuncti ...
Full textLink to itemCite
Book section · 2005
Featured Publication
The National Institutes of Health has established a clinical transplant research program focusing on translational research in kidney transplantation. The program has been developed with a multidisciplinary approach under a common administrative structure ...
Link to itemCite
Journal articleTranspl Immunol · 2004
Featured Publication
Organ transplantation has become a standard life-saving therapy for many causes of end stage organ failure. Although valuable, it remains hampered by the requirement for, and complications of, immunosuppression to prevent immune rejection of the transplant ...
Full textLink to itemCite
Journal articleTransplantation · July 15, 2003
Featured Publication
BACKGROUND: Profound T-cell depletion before allotransplantation with gradual posttransplant T-cell repopulation induces a state of donor-specific immune hyporesponsiveness or tolerance in some animal models. Alemtuzumab (Campath-1H, Millennium Pharmaceuti ...
Full textLink to itemCite
Journal articleTransplantation Reviews · 2003
Featured Publication
In summary, the results from these studies suggest that, in addition to their typical roles as antigen-processing cells serving to initiate an adaptive immune response, monocytes and macrophages may also play an effector role during rejection in patients w ...
Full textLink to itemCite
Journal articleLancet · November 23, 2002
Featured Publication
Renal allograft recipients generally need to take several immunosuppressive agents for life. Calcineurin inhibitors and glucocorticosteroids are the mainstays of most regimens but have undesirable chronic effects. We postulated that aggressive T-cell deple ...
Full textLink to itemCite
